DocGo - Earnings Call - Q1 2025

Executive Summary

• Q1 2025 revenue declined to $96.0M, driven by the wind-down of migrant-related programs; GAAP gross margin compressed to 28.2% and adjusted EBITDA was a loss of $3.9M.
• Management removed all non‑migrant Government Population Health revenue from FY2025 guidance and cut revenue outlook to $300–$330M from $410–$450M; adjusted EBITDA outlook moved from ~5% margin to a loss of $20–$30M, citing public policy and municipal uncertainty.
• Core franchises showed resilience: Transportation Services revenue grew year over year to $50.8M with record trip volume; Payer & Provider assigned lives surpassed 900k, and patient NPS remained strong at 86.
• Cash generation and balance sheet: Operating cash flow was +$9.7M in Q1; cash and restricted cash ended at ~$103.1M; 1.95M shares were repurchased for ~$5.8M.
• Key incremental themes: aggressive SG&A cuts, AR collections (migrant-related AR ~$120M at quarter-end) supporting positive cash flow; M&A optionality (PTI Health acquisition) to expand in-home diagnostics.

What Went Well and What Went Wrong

What Went Well

• Transportation Services revenue rose to $50.8M YoY with record trip volume; segment adjusted gross margin was 33.3% and improved >300bps sequentially vs Q4 2024, supported by wins in multiple markets.
• Payer & Provider momentum: assigned lives exceeded 900k; management highlighted tripled care gap visit volumes vs last year and an NPS of 86, positioning this vertical for higher long‑term margins as clinician utilization improves.
• Positive operating cash flow (+$9.7M) despite a net loss, aided by AR collections; cash and restricted cash remained >$100M, enabling buybacks and targeted M&A (PTI Health).

Quote: “We plan to aggressively cut SG&A over the next several quarters, and anticipate positive cash flow through the balance of the year driven by collections of our outstanding migrant-related receivables.” — CFO Norm Rosenberg.

What Went Wrong

• Top‑line miss vs consensus and sharp guidance reset: Q1 revenue of $96.0M vs S&P Global consensus of $104.2M*, EPS of -$0.09 vs -$0.04*; management removed non‑migrant Government Population Health from FY2025 guidance due to policy‑driven uncertainty.
• Margin pressure: GAAP gross margin fell to 28.2% and adjusted gross margin to 32.1% vs prior year; early-stage Payer & Provider mix diluted Mobile Health margins during scale‑up.
• Elevated SG&A as a percent of revenue (46.7% vs 26.8% YoY) during transition off migrant programs; adjusted EBITDA swung to a -$3.9M loss from +$24.1M YoY.

Transcript

Operator (participant)

Good afternoon, ladies and gentlemen, and welcome to the DocGo first quarter earnings conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, May 8, 2025. I would now like to turn the conference over to Mike Cole, VP of Investor Relations. Please go ahead.

Mike Cole (VP of Investor Relations)

Thank you, Operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements made in this conference call, other than statements of historical fact, are forward-looking statements. The words will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions may be used to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance, and we cannot assure you that we will achieve or realize our plans, intentions, outcomes, results, or expectations. Forward-looking statements are inherently subject to substantial risks, uncertainties, and assumptions, many of which are beyond our control and which may cause our actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in our forward-looking statements.

These risks, uncertainties, and assumptions include, but are not limited to, those discussed in our risk factors and elsewhere in DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, our earnings release for this quarter, and other reports and statements filed by DocGo with the SEC to which your attention is directed. Actual outcomes and results, or the timing of results or outcomes, may differ materially from what is expressed or implied by these forward-looking statements. In addition, today's call contains references to non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in our earnings release or the current report on Form 8-K that includes our earnings release, which is posted on our website, docgo.com, as well as filed with the SEC. The information contained in this call is accurate as of only the date discussed.

Investors should not assume the statements will remain relevant and operative at a later time. We undertake no obligation to update any information discussed in this call to reflect events or circumstances after the date of this call or to reflect new information or the occurrence of unanticipated events, except as to the extent required by law. At this time, it is now my pleasure to turn the call over to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.

Lee Bienstock (CEO)

Thank you, Mike, and thank you all for joining us today. I wanted to start this call discussing the important decision we made to remove our government population health vertical from our 2025 guidance and then outline the growth plans we have for our hospital system, medical transportation, and payer-provider verticals, both for this year and for next. First, regarding our government population health vertical, ongoing policy changes and budget cuts in Washington have created substantial uncertainty and indecisiveness with regard to new municipal project launches and the government RFP channel in general. In fact, we are seeing substantial delays with regard to municipal decision-making and delays in launch timelines for contracts we've already signed. We have 35 open government RFP submissions in our pipeline, a number of which were submitted over six months ago that we are still waiting to hear back on.

Moreover, we have signed contracts in this vertical which were ready to be launched, whose implementation has been put on hold as a direct result of this channel's uncertainty. Accordingly, we can no longer rely on these to generate meaningful revenue this calendar year. As a result, we have decided to move non-migrant government population health revenue and related projects from our 2025 guidance. Along with this decision, we revised our 2025 guidance from $410 million-$450 million in revenue, with a 5% adjusted EBITDA margin, to $300 million-$330 million, with an expected adjusted EBITDA loss of $20 million-$30 million. I want to be clear: this revision to guidance is specifically associated with our government population health vertical. The rest of our business continues to perform as anticipated, and we believe it is on a solid growth trajectory.

This year, we continue to expect approximately $225 million in revenue from our medical transportation services, $50 million from our payer and providers, and $50 million from our remaining migrant services healthcare work, all unchanged from our previous expectations. Any new municipal work would be incremental to our revised 2025 guidance, which, if realized, we plan to break out as upside revenue in future quarters. We are building our company around our innovative solutions for payers, providers, and health systems, and we are incredibly confident in our mobile health at any address and medical transportation offerings. I see these businesses as both the foundation and the future of DocGo, and I am excited to share our key metrics and projected growth rates for this year and the next.

Our medical transportation business continues to perform well and, on a contribution basis, is expected to have adjusted EBITDA of greater than $15 million in 2025. We had record trip volume in the first quarter of 2025 and expect this momentum to continue in the second half of this year, ending 2025 at approximately 575,000 total transports. Beyond that, we project continued top-line growth driven by a major new customer win in the Northeast and continued expansion in the Texas and U.K. markets, and we believe we can approach 700,000 transports by the end of 2026. Health systems continue to search for partners that can provide high-quality, technology-enabled medical transportation solutions that deliver timely, reliable service for their patients. We have invested in building a technology platform that integrates with industry-leading EHRs, including Epic, and provides unmatched transparency for our customers and their patients.

We consistently receive positive feedback from our health system partners and believe that our technology is a key differentiator that enables us to secure new contracts. In our payer and provider vertical, we continue to see substantial growth, and I am pleased to share that we have now exceeded 900,000 assigned lives since the inception of our care gap closure program, up from 700,000 just a quarter ago. In addition to the growth in our number of assigned lives, I wanted to share how our volume of visits has grown over time. In the fourth quarter of 2023, we completed approximately 2,500 care gap closure and transitional care management visits. In the fourth quarter of 2024, our number of care gap closure and TCM visits grew to over 4,400. In the fourth quarter of 2025, we are projecting to complete over 11,500 care gap closure and TCM visits.

In other words, this business is on track to quadruple in size over a 24-month period. We are working with our payer customers to continue expanding our capabilities with evergreen services like pediatric care gap programs, which have seen a significant increase in volumes, with over 2,500 visits completed so far this year. These services include well visits, vaccinations, and fluoride treatments for underserved children. In addition, we recently signed our first substantial PCP agreement with a major payer in the Northeast, which is a very significant step forward in our long-term strategic vision. To put this in perspective, in 2024, we completed 144 PCP visits. That number is expected to grow to 10,000 this year and over 40,000 in 2026. Additionally, in Q1, we added PTI Health, a mobile lab collection and phlebotomy company, to our portfolio.

They are on track to complete over 125,000 blood draws in patient homes in 2025, and we expect them to exceed 200,000 in 2026. All told, between our CareGap program, PCP, and mobile lab businesses, we expect to visit over 150,000 patients in their homes this year. We continue to believe that our ability to bring care to the home in an economic and efficient manner at scale puts us in a uniquely valuable strategic position. Not only can we work to positively impact patient outcomes and drive savings for our payer customers, but we can also gain a significant data advantage in the home regarding the variables that directly impact a patient's health.

We are literally capable of taking a patient from one end of the spectrum to the other, from unengaged with little data and chronic conditions going unaddressed to engaged with complete in-home data while facilitating preventative care. The savings are substantial, and we are positioning the company to capture a larger and larger portion of those savings over time. In addition to the economic savings and improved outcomes, patients absolutely love our service. In Q1, DocGo's mobile health net promoter score was 86, which is substantially higher than the healthcare industry average NPS of 58.

Turning to EBITDA, the primary driver of the anticipated adjusted EBITDA loss for 2025 is our elevated SG&A level as a percentage of revenue during this period of transition, as we wind down our migrant-related business while we invest to support our growing medical transportation and payer-provider mobile health verticals, as well as our technology advantage. While we are making these investments, which we believe will deliver a significant return over our three-year growth plan, we have also initiated cost-cutting measures. We reduced SG&A by approximately $3.1 million on a sequential basis during the first quarter of 2025 and plan to aggressively cut SG&A over the next several quarters as well. We believe that these measures will help us achieve positive adjusted EBITDA in 2026. Now, regarding our balance sheet, which remains healthy.

While we are projecting a consolidated adjusted EBITDA loss for the year, we continue to anticipate positive cash flow from operations and expect to exit the year with over $110 million of cash, after accounting for $9 million of year-to-date stock repurchases, $4 million for the acquisition of PTI, and repayment of $30 million on our revolving line of credit, which will enable us to exit the year debt-free. We continue to build a company that offers a unique value proposition for payers, providers, and health systems, and our growth in 2025 and beyond will be based on the results of our proven medical transportation and rapidly growing mobile health payer and provider businesses. In the event we mobilize any significant non-migrant municipal work this year, revenue from those projects will be reported separately in future quarters and will serve as upside to our 2025 guidance.

In summary, in 2025, we expect our medical transportation business to generate $225 million in revenue, our payer and provider business to generate $50 million, and $50 million from our remaining migrant services healthcare work. We are engaged in cost-containment measures on our SG&A base, and we have a strong balance sheet to fund and support our continued business expansion. I am confident in the demonstrated value of our company and our offerings, and I'm excited about our future plans. Now I'll hand it over to Norm to cover the financials.

Norm Rosenberg (CFO)

Thank you, Lee, and good afternoon. Total revenue for the first quarter of 2025 was $96 million compared to $192.1 million in the first quarter of 2024. The revenue decline was entirely due to the government vertical, primarily in migrant-related projects. As we've pointed out, over the past several quarters, our migrant-related work peaked in the fourth quarter of 2023 and the first quarter of 2024 and began to wind down in May of 2024 with the exit from the New York City-based sites. By the end of 2024, we had exited all of the HPD sites, and the remaining migrant work with New York City Health and Hospitals is expected to be substantially completed by the midpoint of this year.

Mobile health revenue for the first quarter of 2025 was $45.2 million, down from $143.9 million in the first quarter of last year, driven by this anticipated wind down of migrant revenues. Medical transportation services revenue increased to $50.8 million in Q1 of 2025 from $48.2 million in transport revenues that we recorded in the first quarter of 2024. Revenues were driven higher by increases in several markets, including Delaware, Tennessee, Pennsylvania, New Jersey, Wisconsin, Upstate New York, and the U.K. In the first quarter, mobile health revenues accounted for about 47% of total revenues and medical transportation for 53%. We recorded a net loss of $11.1 million in Q1 of 2025 compared with net income of $10.6 million in the first quarter of 2024, reflecting the drop in revenues that I just described.

Adjusted EBITDA for the first quarter of 2025 was a loss of $3.9 million compared to adjusted EBITDA of $24.1 million in the first quarter of 2024. Total GAAP gross margin percentage during the first quarter of 2025 was 28.2% versus 32.8% in the first quarter of 2024. The adjusted gross margin, which removes the impact of depreciation and amortization, was 32.1% in the first quarter of 2025 compared to 35% in the first quarter of 2024. During the first quarter of 2025, adjusted gross margin for the mobile health segment was 30.8% versus 35.5% in the first quarter of 2024, with the biggest impact coming from the early-stage payer and provider business. As that business grew, while migrant revenues declined, the payer and provider business had a larger impact on overall mobile health gross margins.

As this business continues to grow, however, we would expect to see improved utilization rates for our clinicians, which make up the bulk of the cost of goods sold. We expect this improved utilization to lead to higher gross margins for this business line and to eventually raise the overall mobile health segment in the future. In the medical transportation segment, adjusted gross margins were 33.3% in Q1 2025 compared to 33.7% in Q1 of 2024. While medical transportation margins improved by more than 300 basis points on a sequential basis when compared to the fourth quarter of 2024, they were still impacted in Q1 by some higher personnel-related costs in one of our larger markets. As we move forward in 2025, we would expect medical transportation gross margins to continue to improve sequentially.

Looking at operating costs, SG&A as a percentage of total revenues was 46.7% in the first quarter of 2025 compared to 26.8% in the first quarter of 2024. As migrant revenues have wound down over the past several quarters, we've seen SG&A increase sharply as a percentage of total revenues. However, on an absolute dollar basis, SG&A expenses were 13% lower year-over-year in the first quarter of 2025, and they were down 7% on a sequential basis from the Q4 2024 level. We are taking costs out of the business, and we will continue to focus on lowering our SG&A costs throughout 2025, but we do expect that SG&A expense will remain elevated as a percentage of revenues when you compare it to our previous levels for the next several quarters.

Despite the net loss and the negative adjusted EBITDA, we generated $9.7 million in positive cash flow from operations in Q1 as we continued to collect our older, larger invoices. However, our cash balance is lower at the end of Q1 than at the end of 2024 as we spent on our stock buyback program and the acquisition of PTI Health. As of March 31, 2025, our total cash and cash equivalents, which include restricted cash, was $103.1 million, down a little from $107.3 million at the end of 2024, but up about $44 million from the same time last year. Our accounts receivable continued to decrease, reflecting our cash collections and the wind down of migrant revenues that we've witnessed since the middle of the second quarter of 2024.

At quarter end, we had approximately $120 million in accounts receivable from the various migrant programs, which represented about two-thirds of the total company consolidated AR. This compares to $150 million in migrant program-related AR at the end of 2024, which represented approximately 71% of the company total at the time. While the wind down of migrant-related programs has obviously had an impact on revenues, our balance sheet is expected to benefit substantially in 2025 as we collect this AR, leading to an improvement in cash flow from operations, which should be enough to cover any operating losses. Despite the expectation for negative adjusted EBITDA in 2025, we still expect to be operating cash flow positive for the year, given these positive changes in our working capital.

While we're sometimes disappointed about the pace of the payments from New York City, these payments are being made regularly, and we expect the continued collection of these receivables to contribute to an improvement in our overall cash balances. We believe that this will provide us with the resources we need to invest in our growth and to bolster our balance sheet. One of the ways that we deployed our cash during the first quarter was to execute our stock buyback program. During the quarter, we repurchased nearly 2 million shares via open market purchases for an aggregate amount of approximately $5.8 million. So far in Q2, in accordance with the terms of our 10b5-1 trading plan, we have repurchased another 1.2 million shares for an additional $3.2 million.

Having spent close to $9 million on our repurchases so far this year, we still have another $13 million remaining under this program. We also used our cash balance during the quarter to add to our capabilities as we acquired PTI Health, a mobile lab collection and phlebotomy company. We are considering further acquisitions over the rest of 2025 as we seek to continue to use our resources to add to our reach and clinical service offerings. At this point, I'd like to turn the call back over to the operator for Q&A. Operator, please go ahead.

Operator (participant)

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star followed by the number one on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press star followed by the number two. If you are using a speakerphone, please make sure to lift your handset before pressing any keys. Your first question comes from the line of Ryan MacDonald from Needham. Please ask your question.

Ryan MacDonald (Senior Analyst)

Hi, thanks for taking my questions. Sorry to hear about the uncertainty within the government vertical, but maybe let's start there. As you think about the remainder of the year on a quarterly basis, can you just give us a sense of sort of the, you know, how much government revenue each quarter you're kind of expecting and how we should think about the balance of where that gets pulled out? How are you thinking about strategically balancing out, cutting SG&A to sort of optimize the P&L with making sure you have sort of, you know, the staff ready to sort of kick off these government engagements if and when they do kick off later this year or into 2026? Thanks.

Lee Bienstock (CEO)

Absolutely. Thanks, Ryan. Appreciate the question. In terms of the government population health vertical, we made the decision to remove those revenues from our 2025 guidance. Any meaningful population health revenues coming from the non-migrant population health programs, we're going to report on separately as upside in addition to the 2025 guidance that we just revised today. Any material new deployments in the government population health vertical will be described and explained and reported separately moving forward this quarter and into next quarters for the remainder of the year. We are seeing, you know, substantial delays in timelines. We were awarded various different contracts that were expected to launch but have not launched just yet. We submitted multiple RFPs that we should have heard back from but are waiting to hear back on.

As those RFPs come to fruition, as those projects that we've already signed get launched, we'll report on that in the coming quarters. That will be in addition to this revised 2025 guidance that we updated today. In terms of the SG&A base, you hit the nail on the head. We're balancing both restructuring and reinvesting in the different parts of our business. As Norm mentioned, we are absolutely undertaking a look at all of our shared savings, shared services departments, looking for savings in those departments. We're also reinvesting resources into the growing parts of the company on the payer and provider side and the medical transportation side. We do anticipate further growth throughout the remainder of this year and into next. We want to make sure that we're positioned and ready for that growth.

We have a lot of great team members that are helping scale the business. We are going to reinvest those team members into the growing parts of the business and the new areas of focus for the company. Yes, we are undertaking a rigorous look at restructuring some of the various shared services departments for savings that we can cut for SG&A there.

Norm Rosenberg (CFO)

Ryan, it's Norm. You had asked about the impact of the removal of these government revenues from our guidance. You know, using a round number, let's say about $100 million or so. You know, as you recall, we talked about in the past, we talked about how we might have expected Q2 to be the low point of revenue for the company back when we were looking at having all that government revenue in here. Q2 obviously would be when the full wind down would occur on the migrant program. A lot of the stuff that Lee's alluding to, that either we have a signed contract for, but it hasn't launched, or the stuff that we're waiting to hear about would have kicked in in Q3 and Q4.

I think that when we look at it now, I would say that Q2 revenue, obviously, as we always expected, will be lower than what you saw here in Q1. Q3 will probably decline further because there will not be any migrant revenue, any material migrant revenue in that period. We are not counting on any of this government revenue coming in. We probably get a little bit of a blip up from Q4 to Q3, although Q4 will remain below the levels of Q2. That is sort of how the quarterly trajectory changes with the changes we have made to the guidance.

Ryan MacDonald (Senior Analyst)

Yeah, I appreciate all that color there. You know, maybe onto better topics. You know, the payer business continues to really continue to grow at a rapid clip, and it seems like you're experiencing a lot of success there. Can you just talk about sort of the end market demand that you're seeing within the payer segment? You know, obviously, we've heard a lot of commentary out of UnitedHealth that, you know, there's a number of lives transitioning, you know, that were unmanaged MA lives into new plans. Just wondering if that's creating sort of an incremental level of demand for the care gap closure offering. And then any early signs of success on some of the AB testing that you've been doing to sort of improve patient engagement within that care gap closure program? Thanks.

Lee Bienstock (CEO)

Absolutely. As you mentioned, Ryan, we're seeing healthy demand in the care gap closure, PCP, basically healthcare at any address, healthcare in the home business for the exact reasons you mentioned. First off, the plans we're working with, they want to solve for either one or both of two key objectives. One is they absolutely want to reduce their medical loss ratio. They want to reduce their healthcare spending. Our preventative, proactive screenings that we do in the home, the proactive healthcare that we're providing in the home is absolutely targeted at reducing ED readmissions, hospitalizations, and we're seeing very, very good success. Our cohorts of patients are being readmitted to the hospital at much lower rates. That is absolutely something that the health plans are focused on. Obviously, they don't want their members in the hospital. That's where they're most expensive.

As you mentioned, the medical expenses are obviously rising. MLR is a big, big, big focus for these plans. We're helping them with that. The second piece also is we help plans with their quality metrics. The more and more care gaps we're able to close in the home, the better that their quality metrics and their HEDIS measures will increase. You mentioned additional MA members coming to the market. That will absolutely help them with enrollments. That will help them with plan choice and people choosing those MA plans. The higher quality they are, obviously, the more attractive they are to MA members. We're helping in both those scenarios. We average for every visit we do in the home, we're right now averaging about two care gaps closed. For every visit, we're averaging more than one care gap.

In some cases, we've even closed six care gaps in one visit. You can imagine how creative that is for the health plans. Obviously, as some of these managed plans and as the managed market in general gets bigger, we predict over the coming years here, you know, we're going to have more and more of a role to play.

Ryan MacDonald (Senior Analyst)

Excellent. Great to hear. Thanks for the color. I'll hop back in the queue.

Lee Bienstock (CEO)

Thanks, Ryan.

Operator (participant)

Your next question comes from the line of Pito Chickering from Deutsche Bank. Please ask your question.

Kieran Ryan (Equity Research Associate)

Hi there. This is Kieran Ryan on for Pito. Thanks for taking the questions. Just wanted to see if we could get a little bit more color on just kind of what exactly happened since, you know, the end of February when you last reported through the end of this quarter. Because it's kind of looking at even at 1Q result, it looks like it's a decent miss there. Just wanted to understand if there was anything that got canceled in March or just if you could just talk about kind of the quarter and how that plays into, you know, the decision with the guidance. Thank you.

Lee Bienstock (CEO)

Absolutely, Kieran. Absolutely. As we mentioned in our prepared remarks, the revision, it's directly tied to the decision that we made regarding the government population health vertical and how we project and report, you know, those revenues going forward. Our medical transportation, our payer provider business, that's right on track. Our expectations are unchanged there. What changed specific to the government population health vertical is that there's substantial indecisiveness and hesitation. It's been created all the way from the federal level down to municipalities. These policy changes that have been coming out of Washington. You know, as I mentioned, we signed contracts that are stalled. We're waiting on the RFP channel.

Until more clarity emerges, we decided, as you mentioned, between the last call to this call, you know, we decided to remove those from the revenue guidance and they'll serve as sort of upside and we'll report on them, you know, separately. That's what's changed. When you take out approximately the $100 million, as Norm mentioned, from the revenue guidance, that's just the nature of the business model swings. The positive EBITDA expectation of 5%, you know, it moves to the $20 million-$30 million adjusted EBITDA loss when you take out that revenue. Again, in the event that that vertical stabilizes and we do generate meaningful revenues from it, it'd be incremental upside. We'll break that out accordingly. You know, at the same time, you know, as I mentioned, we see great progress in the payer and provider vertical.

I think you hear that coming out here. As well as our medical transportation vertical, we're focused on servicing that demand. We're making sure we provide a clear picture on the fundamental performance of those verticals. We shared a lot more key metrics on those verticals today on this call. We're going to continue to share that in the calls going forward. Really, you know, to summarize what changed from, you know, last call to this call is we made the very conscious decision and the strategic decision to essentially pull those municipal revenues from the guidance and have them report separately and as upside in the coming future quarters.

Norm Rosenberg (CFO)

Yeah. And.

Lee Bienstock (CEO)

Thanks.

Norm Rosenberg (CFO)

Kieran, in terms of what impact it was on the first quarter versus the expectation. Yes, even compared to our internal numbers, you know, I think we were probably on the top line. We were rounding it off. We were right about $100 million as an expectation. We came in at $96 million. Looking at the pieces, the transport actually came in a little bit higher than what we thought. You know, most of our markets were, you know, a couple hundred grand higher than maybe what we thought and on balance a few hundred thousand higher. The migrant revenue in itself, which was about $36 million for the quarter, was a little light compared to what we had mapped out based on the dates. Certain dates had changed on us a little bit. You lost a couple of days here and there.

You also had the wind down happening on a slightly different trajectory. When you're dealing with that larger number, obviously, even a little bit of a change in terms of the number of shifts, the number of personnel, you know, is something that is going to move. That is the part of the business that is going away anyway. Within mobile health, the part of our business that provides staffing to general government programs was also down a little bit. I'm not going to say that is because of the general uncertainty that we're talking about. That was probably just a matter of performance in the way that happened in the quarter. That is, you know, the miss, if you will, on the top line compared to the expectation was entirely contained by the government vertical.

Kieran Ryan (Equity Research Associate)

Got it. That's helpful on the quarter. Thank you. Just quick follow-up just on the other payer provider verticals. Appreciate the extra disclosures. Just wanted to understand kind of how you're thinking about that ramping on revenues and EBITDA, if we think about it just kind of for those two. I think you had said it was $50 million in revenue on that. Just trying to get an idea if you're still kind of actively onboarding new projects there. It's just hard to see, you know, with all the other changes. Thanks for taking the questions.

Lee Bienstock (CEO)

Absolutely. We absolutely are onboarding new programs there. We actually think it's going to pick up with pace in the back half of the year as plans look to close out the year strong to address patients that have open gaps in care and really try to, we see tremendous velocity heading into the back half of the year. We are still onboarding new customers there. We have a very robust pipeline there. Each quarter as we go here, we're expected to do more and more care gap visits and PCP visits as we progress through the year and, of course, into next year. Absolutely there. In terms of the margins, essentially for that business, it's an early stage business. We're ramping scale there right now. We expect those margins for that business to be approaching 40% gross margin next year.

This year, we're still in suboptimal margins as we scale and build density in the markets that we're really focused on. We're really, really excited about the growth of that business. Patients absolutely love it. The plans are loving it. As plans, as was mentioned earlier, as plans are looking to close the year, they have to address patients that have open gaps in care, patients that haven't gone to see their doctor. We're able to address those patients and go see them in the home and bring a new modality of care that perhaps they haven't been available to. We're seeing tremendous, tremendous adoption there. We're also investing pretty heavily in our patient conversion and patient engagement operations.

When we get lists of patients from the payers that have open gaps in care, we're building a world-class engine of how we engage those patients, how we schedule those visits, how we book the clinicians, how we route the clinicians, how we stack those visits so that the clinicians have a full, productive, quality day in the field. As we do that more and more, the margins are just only going to improve from there. We're really excited about what we're building there. The patients love it, as I mentioned. I think we're going to continue to reinvest a lot of our resources into that business. The $50 million that you mentioned, that's unchanged. That's been our number. That's our target. We're on target to hit that. Nothing has changed with that payer and provider goal.

In fact, you know, if anything, I think, you know, we're ahead of schedule there.

Norm Rosenberg (CFO)

Yeah. You have to look ahead, Kieran, because at this point, as Lee is pointing out, that business is a drag on the overall consolidated margin. I would say it maybe costs us a point to a point and a half of the overall consolidated margin, adjusted gross margin that we reported of 32.1%. Ultimately, that business becomes our highest margin business. We have lines of business within that particular vertical that are going to be 50% plus gross margin businesses. That eventually is obviously going to bring the consolidated number up. As far as a leading indicator, it is important for us to look at KPI and leading indicators because, you know, we are looking to the future. The biggest driver of that is obviously the utilization rate of the clinicians, right?

The more trips they can see or more trips they can do or patients they can see in an hour or a 10-hour shift, 8-hour shift, you know, the higher the margin goes. I will say that the early indications there are encouraging. The utilization rate to date, the first, what is it, five weeks of Q2 are about 30% higher than what they were in Q1. They're trending, if this trend continues, they're trending at a level that we hadn't really projected out until sometime in 2026 or 2027. If we can keep those kinds of numbers going as we scale, then I think you might even see a steeper ramp towards that very robust and healthy gross margin. At the moment, if you look at Q1, definitely was a drag on the overall gross margin of the business.

Kieran Ryan (Equity Research Associate)

Thanks a lot. Appreciate it.

Operator (participant)

Your next question is from the line of Sarah James from Cantor Fitzgerald. Please ask your question.

Hey, everyone. This is Gabby on for Sarah. I had a quick question. I had that the government sector revenue was about $100 million, but it looks like guidance was taken down $115 million. Can you just talk about the delta between those two or if that's just implied conservatism in the guidance?

Norm Rosenberg (CFO)

Yep. Yeah. The latter part of your statement is correct. In fact, Lee, a couple of times in his comments earlier said that we're staying on the $225 million for transport. We're sticking at $50 million for migrant, $50 million for these care gap closures and payer programs. That actually, you know, obviously adds up to $325 million as opposed to our range of $300 million-$320 million, which would have, or $300 million-$330 million, which would put you at $315 million. So that's really what it is. We're just trying to be prudent and build something in for the range of possibilities on all our business lines.

Okay. Awesome. Then your comment that 26 should be EBITDA positive, does that imply EBITDA positive without any contribution from the government vertical? Quickly on the payer and provider business, are you seeing a positive, more positive conversations from the positive 2026 MA rates and maybe the payers having more flexibility to apply some of your services?

Lee Bienstock (CEO)

Yeah. As was mentioned, the municipal population health vertical, yes, that would be in addition going forward and also into 2026 as well. That is our plan to report on that in addition to the revenue guidance we are giving today and in the future. That would be in addition to our EBITDA projections for next year. In terms of the payer and what is going on in the MA market, we absolutely view that as a tailwind. We are seeing that. I think we have had many, many opportunities in our pipeline going back all the way to last year. We see the pipeline even over the last two weeks really heating up, which we expected going into the sort of back half Q3 and Q4 of this year. We are seeing a tremendous demand for those services.

Part of it is due to the macro factor of what's going on in the MA market. But also part of it is just we're getting more and more data. And our pitch is just getting stronger and stronger because we're able to show the ROI. We're able to show the patient happiness. We're able to show the impact we're having. We're able to show how many patients we've even been able to close care gaps with. They're reporting back to their plans that they're happy with the service. Obviously, patient satisfaction, member satisfaction is a big component of the quality score for the MA plans. All of that is also helping us as we scale. Not only do we improve our operations, but as we scale, we just have more and more data, more and more experience, more and more references for other plans.

Plans are sharing us from one state to the next and referring us. All of that as we perform well. We are investing. We want to make sure that these plans love us. We want to make sure because there is just so much opportunity. We want to make sure that the patients love us. We are really improving their health outcomes. Once we are able to do all of that, you know, there is a tremendous opportunity ahead of us.

Okay. Awesome. Thank you, guys.

Thanks, Gabby.

Operator (participant)

Your last question is from the line of David Larsen, Larsen from BTIG. Please ask your question.

Jenny Shen (Equity Research Associate)

Hi. This is Jenny Shen on for Dave. I apologize if I've missed this if you had mentioned it, but can you remind us what the margin profile is of the migrant-related revenue versus your core business? Then just quickly on tariffs, I know we've spoken about the expected impact on your fleet and the costs to manage your fleet. Do you have any potential risk from tariffs on some of your medical equipment that you use and wearable devices in the home? Thank you.

Norm Rosenberg (CFO)

Okay. So I'll start with your question about the margin profile on the migrant program. The margins on that program were about 34%. And it's pretty consistent, actually. It was 34% in Q4, 34% again, give or take in a few basis points in Q1. When you look at it that way, in the fourth quarter, our gross margin for mobile health was 35.9%. Technically, the rest of the non-migrant piece of mobile health was being driven at a higher margin. Here it was the other way around. The fact that the mix moved away from migrant and towards the other things, such as the payer and provider programs, that obviously brought down the margins. The mix brought it down. I would say right about 34% or so is the number that we're seeing from the migrant work.

Do you want to take a tariff on or do you want to?

Lee Bienstock (CEO)

Yeah. With regards to tariffs, Jenny, exactly as you described, I think the tariffs would be related to our fleet. Obviously, we have a substantial fleet of almost 1,000 vehicles in the fleet. I think the tariffs, the way it would be factored in is we have a calculation that we look at as to when we procure new vehicles versus maintain the ones we have. We look at the balance between perhaps the rising cost of procuring a vehicle or the cost going forward of just maintaining the ones we have. We are in a good position to be able to balance that. We have a relatively new fleet in general. In addition, we have a wonderful and dedicated fleet management team that is able to keep our vehicles on the road.

Once a vehicle becomes more expensive to maintain, that's when we procure a new one. The tariffs may impact that calculation, but I'm confident that our team is doing a wonderful job maintaining the vehicles that we have. We had already placed orders on the new fleet that we were going to procure for this year, which has been placed and priced and paid for. I think we are in a good position. It could increase the prices for some of the parts. You know, obviously, we drove 8.8 million miles last year. That's oil changes and tires and brake pads and everything you can imagine that keeps that tremendous fleet on the road. Ultimately, we'll look at the cost of maintaining, the cost of procuring new ones. Like I said, we were forward-thinking and we have great scale.

We've been most of our orders that we were looking to procure were already placed this year.

Norm Rosenberg (CFO)

Yeah. On the other hand, fuel costs can go down. I mean, they're currently running already a little bit below what we had projected and a little bit below where they were a year ago. I think the biggest impact is going to be the one that everybody faces, which is the general inflationary environment. Again, even within that inflationary environment, oil prices are probably lower. Gas prices, therefore, will be lower. You know, we have some leverage for that. That would be a net benefit to us.

Jenny Shen (Equity Research Associate)

Great. Thank you.

Operator (participant)

There are no further questions at this time. So I'd like to turn the call over to Mr. Lee Bienstock for closing comments. Sir, please go ahead.

Lee Bienstock (CEO)

Thank you. Thank you all for joining us today. Be well.

Operator (participant)

This concludes today's conference call. Thank you very much for your participation. You may now disconnect.